Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
Bristol Myers Squibb announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating Camzyos (mavacamten) in adult patients with New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback